Takeda, Azurity Settle Patent Suits on Rival Hypertension Drugs

Takeda Pharmaceutical Co. and Azurity Pharmaceuticals Inc. settled patent-infringement lawsuits over generic versions of two hypertension drugs, resolving their cases over a Turkish company’s proposed copy of Edarbi and Alkem Laboratories Ltd.’s proposed generic Edarbyclor, mooting this week’s joint bench trial.

Judge Maryellen Noreika on Monday approved a stipulation and order dismissing Saba Ilac Sanayi ve Ticaret AS in the US District Court for the District of Delaware. She approved the dismissal of Alkem in an order issued Feb. 2. A bench trial that had been slated to start Monday was canceled.

Takeda, Azurity, and Azurity’s Arbor Pharmaceuticals unit sued ...